Evidence map›Paper›PMID 34940751›Full record

ArticleNeurology international2021

The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis.

Vera Damuzzo, Laura Agnoletto, Roberta Rampazzo, Francesca Cammalleri, Luca Cancanelli, Marco Chiumente, Stefano Costantino, Silvia Michielan, Federica Milani, Alessia Sartori and 2 more

Open access · goldAbstract read
In one paragraph

Article in Neurology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Vera DamuzzoDepartment of Pharmaceutical and Pharmacological Sciences, School of Hospital Pharmacy, University of Padua, 35122 Padua, Italy.
Laura AgnolettoPharmacy, Santa Maria della Misericordia Hospital, 45100 Rovigo, Italy.ORCID 0000-0002-6236-362X
Roberta RampazzoRegional Pharmaceutical Office, Veneto Region, 30125 Venice, Italy.
Francesca CammalleriDepartment of Pharmaceutical Sciences, School of Hospital Pharmacy, University of Milan, 20122 Milan, Italy.
Luca CancanelliDepartment of Pharmaceutical Sciences, School of Hospital Pharmacy, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-6409-4195
Marco ChiumenteItalian Society of Clinical Pharmacy and Therapeutics-SIFaCT, 20159 Milan, Italy.ORCID 0000-0002-0943-6746
Stefano CostantinoDepartment of Drug Science and Technology, School of Hospital Pharmacy, University of Turin, 10124 Turin, Italy.ORCID 0000-0001-8177-3264
Silvia MichielanDepartment of Pharmaceutical and Pharmacological Sciences, School of Hospital Pharmacy, University of Padua, 35122 Padua, Italy.
Federica MilaniDepartment of Pharmaceutical and Pharmacological Sciences, School of Hospital Pharmacy, University of Padua, 35122 Padua, Italy.
Alessia SartoriDepartment of Food and Drug, School of Hospital Pharmacy, University of Parma, 43121 Parma, Italy.
Melania RivanoDepartment of Pharmaceutical Sciences, School of Hospital Pharmacy, University of Milan, 20122 Milan, Italy.
Daniele MengatoItalian Society of Clinical Pharmacy and Therapeutics-SIFaCT, 20159 Milan, Italy.ORCID 0000-0003-1374-1505
University of Milan · ITUniversity of Padua · ITOspedale Santa Maria della Misericordia di Rovigo · ITRegione del Veneto · ITUniversity of Parma · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Health-related quality of life is frequently included in patient-reported outcomes aimed at evaluating the effectiveness of disease-modifying drugs for multiple sclerosis, but recent data about Italian patients are missing. A multicenter observational and cross-sectional study was performed by students of hospital pharmacy to update existing data on quality of life and to correlate it with the pharmacological and medical history of patients. Quality of life (QoL) was assessed using the MS-QoL54 questionnaire, and the pharmacist collected patients' characteristics, medical and pharmacological history, and Expanded Disability Status Scale (EDSS). Three hundred and forty-nine patients with multiple sclerosis were recruited from 16 centers between May 2018 and June 2019 (median age = 44.1 years; 68.9% women). The composite indexes of physical and mental well-being showed direct correlation with each other (R = 0.826;

Indexed as

disease-modifying drugshospital pharmacistMS-QoL54multiple sclerosisquality of life

Identifiers

PMID34940751
PMCPMC8706851
OpenAlexW3216278148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.